HealthCare Royalty Partners names managing director
Dr. Cooper initially joined the team in 2016, consulting as an Industry Advisor. He is a UK-trained physician with over 35 years of experience in the global pharmaceutical industry.
HCR’s senior professionals have known Dr. Cooper for over a decade, working closely with him when he served as CEO of Prism Pharmaceuticals.
Prior to serving as CEO of Prism, Dr. Cooper spent 12 years with Merck, initially as a UK clinical research physician, then as head of European and subsequently Worldwide Clinical Research Operations.
Dr. Cooper also previously led AstraMerck’s (now AstraZeneca PLC) cardiovascular division.
HCR has promoted John Urquhart to a Principal of the firm.
Mr. Urquhart has over a decade of healthcare investing experience in the royalty and structured finance market.
Mr. Urquhart was among the first employees at HCR, joining the firm as an analyst in 2007 and re-joining in 2012 after receiving his M.B.A. from The Wharton School of the University of Pennsylvania.
HCR has also promoted Anthony Rapsomanikis to Vice President.
Mr. Rapsomanikis joined HCR as an Associate in 2012, and was promoted to Director of West Coast Business Development after establishing the firm’s San Francisco office in 2015. ■
LATEST MOVES FROM Massachusetts
- Haemonetics Corporation appoints Robert E. Abernathy to board
- Tetraphase Pharma appoints Kamalam Unninayar as CFO
- Boston Biomedical appoints Edgar Braendle as vice president
- Analogic Corporation appoints Joseph Whitters to board
- Eleven Biotherapeutics appoints Richard F. Fitzgerald as interim CFO
More inside POST
Shooping spree: Aramark buys Avendra for $1.35 billion, AmeriPride Services for $1 billion Companies
Richard Branson invests in Hyperloop One Companies